Vanguard Group Inc. Cuts Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Vanguard Group Inc. decreased its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,207,765 shares of the company's stock after selling 37,643 shares during the period. Vanguard Group Inc. owned about 2.39% of Tyra Biosciences worth $16,788,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its holdings in Tyra Biosciences by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock valued at $364,000 after purchasing an additional 1,027 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Tyra Biosciences during the 3rd quarter worth about $593,000. Barclays PLC lifted its stake in Tyra Biosciences by 200.5% in the 3rd quarter. Barclays PLC now owns 37,625 shares of the company's stock valued at $884,000 after buying an additional 25,106 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock worth $8,667,000 after acquiring an additional 3,896 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Tyra Biosciences during the 3rd quarter worth $278,000. Institutional investors and hedge funds own 84.14% of the company's stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several research reports. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush reissued an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Trading Up 4.5 %

Tyra Biosciences stock traded up $0.41 during midday trading on Tuesday, hitting $9.47. 243,858 shares of the stock were exchanged, compared to its average volume of 248,970. The stock's 50-day simple moving average is $10.20 and its 200 day simple moving average is $14.49. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The stock has a market capitalization of $502.76 million, a price-to-earnings ratio of -5.88 and a beta of 1.19.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.05. Equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the transaction, the director now owns 443,885 shares of the company's stock, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 15.40% of the stock is owned by insiders.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.